Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYNJ2 | O15056 | 3/20 | 1.00 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.57 |
| ▸ | GRK2 | P25098 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | TYMP | P19971 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.34 |
| ▸ | CES2 | O00748 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Albiflorin SCHEMBL21164770 | 0.93 | SYNJ2 (0.87) | SYNJ2SLC22A1GRK2 | |
| Albiflorin SCHEMBL21315817 | 0.93 | SYNJ2 (0.87) | SYNJ2SLC22A1GRK2 | |
| Albiflorin SCHEMBL623462 | 0.93 | SYNJ2 (0.87) | SYNJ2SLC22A1GRK2 | |
| Albiflorin SCHEMBL15235363 | 0.93 | SYNJ2 (0.87) | SYNJ2SLC22A1GRK2 | |
| Albiflorin SCHEMBL29500192 | 0.93 | SYNJ2 (0.87) | SYNJ2SLC22A1GRK2 | |
| Albiflorin SCHEMBL24008597 | 0.93 | SYNJ2 (0.87) | SYNJ2SLC22A1GRK2 | |
| Albiflorin SCHEMBL21702839 | 0.93 | SYNJ2 (0.87) | SYNJ2SLC22A1GRK2 | |
| Albiflorin SCHEMBL22648992 | 0.93 | SYNJ2 (0.87) | SYNJ2SLC22A1GRK2 | |
| Albiflorin SCHEMBL13387630 | 0.92 | SYNJ2 (0.85) | SYNJ2SLC22A1GRK2 | |
| SCHEMBL26946999 | 0.91 | SYNJ2 (0.84) | SYNJ2SLC22A1GRK2ALDH1A1TYMP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170042857-A1 | SYNAPTOJANIN-2 INHIBITORS FOR USE IN THE TREATMENT OF CANCER | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2017-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170042857-A1 | SYNAPTOJANIN-2 INHIBITORS FOR USE IN THE TREATMENT OF CANCER | SNAP29, SYNJ1, TPX2 | SYNJ2 6/4885SLC22A1 2626/4885GRK2 283/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.